구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Genetically Engineered Hematopoietic Stem/Progenitor Cells (Genetically Engineered Hematopoietic Stem/Progenitor Cells) Centro de Investigaciones Energéti…·Fanconi Anemia 12 trials |
|---|---|
Overview Program | Genetically Engineered Hematopoietic Stem/Progenitor Cells |
Overview Company | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) |
Overview Modality | CGT |
Overview Target | Fanconi Anemia |
Overview Indication | Fanconi Anemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies.. Antigen-directed immunotherapies for acute myeloid leukemia (AML), such as chimeric antigen receptor T cells (CAR-Ts) or antibody-drug conjugates (ADCs), are associated with severe toxicities due to the lack of unique targetable antigens that can distinguish leukemic cells from normal myeloid cells or myeloid pro… |
Clinical Safety signal | Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies.. Antigen-directed immunotherapies for acute myeloid leukemia (AML), such as chimeric antigen receptor T cells (CAR-Ts) or antibody-drug conjugates (ADCs), are associated with severe toxicities due to the lack of unique targetable antigens that can distinguish leukemic cells from normal myeloid cells or myeloid pro… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Genetically Engineered Hematopoietic Stem/Progenitor Cells (Genetically Engineered Hematopoietic Stem/Progenitor Cells) Centro de Investigaciones Energéti…·Fanconi Anemia 12 trials |
|---|---|
Overview Program | Genetically Engineered Hematopoietic Stem/Progenitor Cells |
Overview Company | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) |
Overview Modality | CGT |
Overview Target | Fanconi Anemia |
Overview Indication | Fanconi Anemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies.. Antigen-directed immunotherapies for acute myeloid leukemia (AML), such as chimeric antigen receptor T cells (CAR-Ts) or antibody-drug conjugates (ADCs), are associated with severe toxicities due to the lack of unique targetable antigens that can distinguish leukemic cells from normal myeloid cells or myeloid pro… |
Clinical Safety signal | Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies.. Antigen-directed immunotherapies for acute myeloid leukemia (AML), such as chimeric antigen receptor T cells (CAR-Ts) or antibody-drug conjugates (ADCs), are associated with severe toxicities due to the lack of unique targetable antigens that can distinguish leukemic cells from normal myeloid cells or myeloid pro… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교